このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

主な急性感染症の静脈内治療と経口治療

2026年11月12日 更新者:University of Southern Denmark

救急部門における主な急性感染症の静脈内治療と経口治療

Patients admitted to the hospital with acute infections are often treated with intravenous (IV) antibiotics. Around 70% of these infections fall into three categories: respiratory tract infections, urinary tract infections, and cellulitis. A Danish study found that 76% of patients admitted with suspected community-acquired pneumonia and treated with antibiotics received them intravenously. Based on an extrapolated estimate from an unpublished local survey, approximately 50,000 patients in Denmark are admitted each year for infections and treated with IV antibiotics. The average hospital stay for these patients is 5.9 days, resulting in a total of 295,000 hospital days annually, accounting for about 7% of total hospital admissions in Denmark. This represents an annual cost of 2.3 billion DKK. While some patients need hospitalization due to their overall health or other serious conditions, others remain hospitalized primarily to receive IV antibiotics.

Expanding the use of oral antibiotics in emergency departments should be pursued only if it can demonstrate comparable efficacy and safety to IV administration. Therefore this study will investigate the efficiency of primarily oral antibiotics in acutely admitted patients with proven or suspected infections. Additionally, the investigators will evaluate the safety of oral regimen for these patients.

調査の概要

状態

募集

条件

介入・治療

詳細な説明

Patients admitted to the hospital with infections are often treated with intravenous antibiotics. The rationale for using intravenous antibiotics includes eliminating the risk of reduced absorption, achieving higher serum concentrations, and the fact that many broad-spectrum antibiotics (such as cephalosporins and carbapenems) are not available in oral form. However, intravenous antibiotics also have drawbacks, such as the risk of catheter-related infections, challenges in home-based treatment, and difficulty switching to oral antibiotics unless microbiological results are definitively positive. Prolonged hospital stays associated with intravenous antibiotic treatment lead to economic burdens, increased risk of hospital-acquired infections, and significant functional decline, especially in older patients.

In recent decades, many studies have explored the possibility of fully or partially replacing intravenous antibiotics with oral antibiotics for certain infections.

In this study, the investigators will examine the safety and efficacy of primarily oral antibiotic regimens in patients with confirmed or suspected infections admitted to the emergency department. The study is an open-label, prospective, randomized controlled trial. Participants will be randomly assigned to receive either standard intravenous antibiotic treatment according to Danish guidelines or oral antibiotic treatment based on tailored recommendations developed by microbiologists and infectious disease specialists at participating sites, in accordance with local guidelines.

The study has two primary outcomes: 1) Efficacy-measured as the number of days alive outside the hospital within 30 days after randomization, and 2) Safety-measured by mortality or the need for vasopressors within 30 days after randomization. A total of 2640 patients will be needed to address both primary outcomes.

Aim: The trial aims to investigate the safety and efficacy of oral antibiotic administration compared to intravenous antibiotic administration in patients referred to the emergency department with suspected or diagnosed bacterial pneumonia, urinary tract infection and cellulitis.

研究の種類

介入

入学 (推定)

2640

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Helene Skjøt-Arkil
  • 電話番号:+45 79971113
  • メール:hsa@rsyd.dk

研究連絡先のバックアップ

  • 名前:Mariana Bichuette Cartuliares
  • 電話番号:+45 79971113
  • メール:mbc@rsyd.dk

研究場所

      • Copenhagen、デンマーク、2400
        • 募集
        • Bispebjerg and Frederiksberg Hospital
        • コンタクト:
          • Frederik Neess Engsig
      • Copenhagen、デンマーク
        • 募集
        • Nordsjællands Hospital
        • コンタクト:
          • Jon Gitz Holler
      • Esbjerg、デンマーク、6700
        • 募集
        • Esbjerg and Grindsted Sygehus
        • コンタクト:
          • Peter Biesenbach
      • Herlev、デンマーク、2730
      • Hvidovre、デンマーク、2650
      • Kolding、デンマーク、6000
        • 募集
        • Sygehus Lillebælt
        • コンタクト:
          • Lone Wulff Madsen
    • Southern Denmark
      • Aabenraa、Southern Denmark、デンマーク、6200
        • 募集
        • Sygehus Sønderjylland
        • コンタクト:
      • Sønderborg、Southern Denmark、デンマーク、6400
        • 募集
        • Sygehus Sønderjylland
        • コンタクト:
          • Christian Backer Mogensen
          • 電話番号:0045 79970000
          • メール:CBM1@rsyd.dk

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Suspected respiratory tract infection, urinary tract infection, or cellulitis by the attending physician
  • Planned or initiated intravenous antibiotic treatment

Exclusion Criteria:

  • if received more than two doses of intravenous antibiotics;
  • systolic blood pressure <90 mmHg;
  • nausea and/or vomiting in more than one short-term instance during the last 2 days;
  • suspected significantly reduced gastrointestinal absorption;
  • confirmed plasma-lactate > 2;
  • pregnant or nursing;
  • unable to give informed consent;
  • severe immunodeficiency;
  • urgent vital treatment needed.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
介入なし:Standard Care

Standard intravenous treatment in accordance with local or national procedures

アクティブコンパレータ:Oral treatment

Oral treatment

Patients randomized to oral treatment will commence the oral treatment immediately. The oral treatment is based on specially developed treatment suggestions developed by microbiologists and specialists in infectious diseases from the participating regions, and in respect with local treatment guidelines (detailed described in the protocol).

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Days alive outside hospital (Efficacy)
時間枠:From randomization date to 30 days

The number of days the patients are alive outside hospital within 30 days after randomization

From randomization date to 30 days
Number of patients requiring treatment with vasopressors
時間枠:From date of randomization to 30 days

Number of patients that die or number of patients that require treatment with vasopressors within 30 days after randomization

From date of randomization to 30 days

二次結果の測定

結果測定
メジャーの説明
時間枠
Length of hospital stay
時間枠:From date of randomization until date of documented hospital discharge or date of death from any cause, whichever came first, assessed up to 6 months

Duration of hospital length of stay in days

From date of randomization until date of documented hospital discharge or date of death from any cause, whichever came first, assessed up to 6 months
Inhospital mortality
時間枠:From date of randomization until date of death in hospital from any cause, assessed up to 6 months

The number of death measured inhospital before discharge

From date of randomization until date of death in hospital from any cause, assessed up to 6 months
30-days mortality
時間枠:up to 30 days from baseline (randomization date)

The number of death within 30 days

up to 30 days from baseline (randomization date)
90-days mortality
時間枠:Up to 90 days from baseline (randomization date)

The number of death within 90 days

Up to 90 days from baseline (randomization date)
One-year mortality
時間枠:Up to one-year from baseline (randomization date)

The number of death within one-year

Up to one-year from baseline (randomization date)
Five-year mortality
時間枠:Up to five-years from baseline (randomization date)

The number of death within five-years

Up to five-years from baseline (randomization date)
Discharge within 24 hours
時間枠:Up to 24 hours after rom baseline (randomization date)

The number of patients discharged within 24 hours

Up to 24 hours after rom baseline (randomization date)
Readmission
時間枠:30 days after discharge date

The number of patients readmitted to hospital

30 days after discharge date
Intensive care admission
時間枠:From date of randomization until date of admission to intensive care during hospitalization due to any cause, assessed up to 6 months

Number of patients admitted to intensive care during current hospital stay

From date of randomization until date of admission to intensive care during hospitalization due to any cause, assessed up to 6 months
Days on antibiotic treatment within 30 days
時間枠:Within 30 days from randomization date

Number of days the patient have been treated with antibiotics

Within 30 days from randomization date
Bacteremia
時間枠:Day 7 to day 30 from randomization date

Number of patients diagnosed with bacteremia

Day 7 to day 30 from randomization date

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年1月15日

一次修了 (推定)

2027年6月1日

研究の完了 (推定)

2032年6月1日

試験登録日

最初に提出

2024年11月5日

QC基準を満たした最初の提出物

2024年12月3日

最初の投稿 (実際)

2024年12月4日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月17日

QC基準を満たした最後の更新が送信されました

2026年11月12日

最終確認日

2026年3月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • SHS-ED-1-2024

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。